Thanks to private funding, 100% of every dollar donated to The Lustgarten Foundation goes directly to pancreatic cancer research.

Learn More about Pancreatic Cancer

Introducing the Pancreatic Cancer Collective

lg.sutc

Together, the Lustgarten Foundation and Stand Up To Cancer have funded more than 170 investigators across 28 leading research centers. The Pancreatic Cancer Collective will build on this momentum.

Newly Diagnosed 


Start here to learn about pancreatic cancer and available resources.

Finding Clinical Trials


 A clinical trial is a research study designed to evaluate a new cancer treatment. Patients enrolled in a clinical trial are among the first to receive new treatments before they become widely offered.

Latest News

Translational research team to test CAR T-cell therapy for pancreatic cancer

Stand Up To Cancer, in collaboration with the Lustgarten Foundation for Pancreatic Cancer Research, is supporting a new translational research team that will explore how chimeric antigen receptor T-cell therapy can be applied to pancreatic cancer.

2.13.18
Read More >

Researchers discover a potential new therapeutic strategy for pancreatic cancer

In most pancreatic cancer patients, the diagnosis occurs when the disease is already advanced, and currently, there is no effective treatment. There have been no significant advances to combat it in recent decades, and unfortunately, its occurrence is on the increase. Now, a group of researchers from the Spanish National Cancer Research Centre (CNIO) may have found a new therapeutic approach. The research is published in the Proceedings of the National Academy of Science (PNAS).

2.02.18
Read More >

Scientists successfully prevent the growth of pancreatic cancer

A respiratory virus has been utilized to effectively restrain the growth of pancreatic cancer as indicated by an early examination by scientists at Cardiff University and Barts Cancer Institute (BCI) of Queen Mary University of London (QMUL). The investigation, supported by the philanthropy Pancreatic Cancer Research Fund, recommends that the new system could possibly turn into a promising new treatment for patients with the forceful ailment, and could be joined with existing chemotherapy to enhance odds of survival.

2.01.18
Read More >

Tempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer Patients

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced a collaboration with NYU School of Medicine aimed at improving outcomes for patients diagnosed with pancreatic cancer.Pancreatic cancer is the third leading cause of cancer-related death in the United States and has a five-year survival rate of just nine percent.

1.25.18
Read More >

Flu Virus USed To Treat Pancreatic Cancer In Mice

Pancreatic cancer is a particularly aggressive and deadly cancer, but now researchers in London have developed a modified flu virus to target and kill tumor cells.The virus has an extra protein that binds pancreatic cancer cells and scientists found the modified virus was able to stop cancer growth in mice..

1.25.18

Read More >

Pancreatic Cancer May Be Accelerated by Stress, Finds Study Findings suggest beta-blockers, which inhibit stress hormones, may increase survival

A new study shows that stress accelerates the development of pancreatic cancer by triggering the release of “fight-or-flight” hormones. Beta-blockers—commonly used medications that inhibit these hormones—were found to increase survival in a mouse model of the disease. An additional analysis of patients with advanced pancreatic cancer revealed that those who were taking beta-blockers for another condition lived approximately two-thirds longer than those who were not taking the medications.

1.11.18
Read More >

Von Hoff's Quest Is for a Cure in Pancreatic Cancer

MaryAnna set the pattern: One of Von Hoff’s earliest memories is sitting on her lap, listening to her read Aesop’s fables each day. In his mid-90s, Stanley was still cutting his neighbor’s lawn and growing vegetables. Just as his father had apprentices, so, too, did Von Hoff, who has taught what he knows to those who came up after him. Sharing Knowledge on a Larger Scale Von Hoff shows immense gratitude for the many people he has learned from, as well as the many he’s had the opportunity to mentor. His curriculum vitae spans 200 pages, including committees, societies, and honors, as well as the postdoctoral candidates he has mentored.His biggest accomplishment, he said, has been the establishment of the AACR-ASCO Methods in Clinical Cancer Research course, a collaboration between the 2 societies.

12.27.17
Read More >

More tumor mutations equals higher success rate with cancer immunotherapy drugs

The mutational burden, or the number of mutations present in a tumors DNA, is a good predictor of whether that cancer type will respond to a class of cancer immunotherapy drugs known as checkpoint inhibitors, a new study led by Johns Hopkins Kimmel Cancer Center researchers shows. The finding, published in the Dec. 21 New England Journal of Medicine, could be used to guide future clinical trials for these drugs.Checkpoint inhibitors are a relatively new class of drug that helps the immune system recognize cancer by interfering with mechanisms cancer cells use to hide from immune cells. As a result, the drugs cause the immune system to fight cancer in the same way that it would fight an infection.

12.20.17
Read More >

Study Prompts New Ideas on Cancers’ Origin

Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer, a finding that could upend the way scientists think about the origins of the disease.Researchers at Washington University School of Medicine in St. Louis have found that mature cells have the ability to revert back to behaving more like rapidly dividing stem cells.

12.18.17
Read More >

Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies.

In the prospective cohort study, 1122 participants developed pancreatic adenocarcinoma over 4.2 million person-years. Use of aspirin or non-aspirin NSAIDs was not associated with pancreatic cancer risk, even after considering several latency exposure classifications. In a pre-planned subgroup analysis, regular aspirin use was associated with reduced pancreatic cancer risk among participants with diabetes (relative risk, 0.71; 95% CI, 0.54-0.94). In the nested case-control study, pre-diagnosis levels of salicylurate were not associated with pancreatic cancer risk (odds ratio, 1.08; 95% CI, 0.72-1.61; Ptrend 0.81; comparing participants in the highest quintile to those in the lowest quintile of plasma salicylurate).

12.13.17
Read More >

How inhibiting one protein could help to treat pancreatic cancer

Targeting an enzyme that makes pancreatic cancer cells more aggressive by silencing some of their genes could make the deadly disease less resistant to treatment. red-colored pancreas in x-ray Could the findings of a new study help in the fight against pancreatic cancer? This was the conclusion of new research from Genentech, a biotechnology company in South San Francisco, CA, which was recently reported in the Journal of Cell Biology.

12.11.17
Read More >

TGen and Baylor poised to create early detection test for pancreatic cancer

A group of the nation's premier cancer researchers led by the Baylor Scott & White Research Institute (BSWRI) and the Translational Genomics Research Institute (TGen) -- has secured a $5.13 million federal grant to develop an early detection system for pancreatic cancer, the nation's third-leading cause of cancer-related death.Because it displays no overt symptoms or pain in its early stages, pancreatic cancer often is not diagnosed until it has spread to other organs, especially the liver and the lungs

12.11.17
Read More >

SU2C SCIENTIFIC RESEARCH TEAMS

Michael G. Goggins, MBBCH, MD, is professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine. He serves as director of the Pancreatic Cancer Early Detection Laboratory and is an attending physician in medicine in the Division of Gastroenterology and Hepatology at The Johns Hopkins Hospital, as well as a molecular biologist.

12.08.17
Read More >

Identifying Unique Antigen Qualities in Long-Term Pancreatic Cancer Survivors

Vinod P. Balachandran, MD, Surgical Oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis to determine the unique antigen qualities of long-term survivors of pancreatic cancer during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

11.16.17
View Video >

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma

Are alterations in the 4 main driver genes for pancreatic adenocarcinoma associated with patient outcomes after pancreatic cancer resection? In this study involving 356 patients with resected pancreatic adenocarcinoma, immunohistochemistry and next-generation DNA sequencing of formalin-fixed, paraffin-embedded pancreatic adenocarcinoma resection specimens identified alterations in the 4 main driver genes (KRAS, CDKN2A, SMAD4, and TP53). Disease-free survival and overall survival were associated with the presence and pattern of alterations in these 4 genes independent of previously identified prognostic factors.

11.08.17
Read More >

Lustgarten Foundation Launches Online Support Community

Today the Lustgarten Foundation for Pancreatic Cancer Research in partnership with Let’s Win, an initiative supported by the Foundation, and Inspire launched an online support community, Pancreatic Cancer Connections, which provides a safe space for pancreatic cancer patients and their loved ones to share their experiences, get valuable coping resources, and support one another. Inspire is a leading healthcare social network that connects more than 1,000,000 patients and caregivers.

11.06.17
Read More >

 

Thanks to private funding, 100% of every dollar donated to the Lustgarten Foundation goes directly to pancreatic cancer research.

415 Crossways Park Drive, Suite D, Woodbury, NY 11797
Toll Free: 1-866-789-1000 P: 516-737-1550 F: 516-584-6265

logos-3-

2015 website development and design sponsored by Celgene